ADORAM THERAPEUTICS

Startup Investment Opportunity 2024

University spinoff, limited corporation founded in Switzerland in 2022

Contact: david.pejoski@adoram.ch

Innovative drugs are needed for prevalent diseases

Inflammation (e.g. arthritis, dermatitis, colitis, and auto-immune related), cancer, & metabolic disorders have a growing impact on society, and current treatments are only effective in a subset of patients. For example, >80 % of solid (GI tract, lung) tumor patients do not achieve positive outcomes with existing immunotherapies.

Adenosine receptors represent essential drug targets

Adenosine and adenosine receptors are highly validated key mediators of multiple biological processes including inflammation, metabolism, and anti-cancer immune responses. Depending on the disease, it would be desirable to increase or decrease signaling of adenosine receptors, for example by positive or negative modulators.

Solid tumors overproduce adenosine that binds to an immune cell surface receptor called A2AR, which then prevents killing of cancer cells. By blocking the adenosine signal, a tumor patient's immune response and co-administered immunotherapies can be greatly enhanced.

Suboptimal molecular mechanism of competitor drugs

Pharmaceutical competitors have attempted to develop drugs that bind A2AR at the same site as adenosine.

In cancer, high concentrations of adenosine in tumors lead to displacement of conventional drugs, & adenosine continues to suppress the immune system. If higher drug doses are administered, toxicity occurs.

In inflammation, conventional A2AR drugs cause systemic immunomodulation rather than only at the sites where adenosine signaling is defective.

Allosteric modulation: inherently better by design

Our negative and positive allosteric modulators (NAMs and PAMs) bind to A2AR at a different site (an allosteric site) to the adenosine binding site, which changes the shape (conformation) of A2AR and either decrease or increase the ability of adenosine to bind or signal.

Clear differentiation over conventional small molecules

Mouse and primary human immune cell data demonstrates high potency, efficacy, selectivity, & an excellent therapeutic window & safety profile of A2AR NAMs for solid tumor immunotherapy, and A2AR PAMs to reduce inflammation.

Explore our translational data here:

Systemic treatment of very high adenosine tumors



Monotherapy efficacy in adenosine rich tumor models

Adoram	MSD Portage
✓	iTeos, InCyte, Evotec Exscientia
Competitors	Novartis Palobio Corvus Genentech
✗	Arcus Gilead Astra Zeneca Heptares Merck Domain

PUBLICATIONS

PCT Patent: A2AR Modulators to treat cancer, 2023, WO2023213761A1

Poster: ESMO Immuno-Oncology Conference 2023, Pejoski *et. al.*, 146P

More efficient & sensitive allosteric drug screening

We discover & develop best-in-class small molecule drugs with a sought-after allosteric mechanism; from hit identification to early clinical. Our in-house molecule library is screened using a proprietary assay & cascade to identify allosteric modulators of GPCR drug targets (the largest class of human receptors) followed by medicinal chemistry & translational drug screening assays. The approach has been benchmarked using 4 different GPCRs, and is more sensitive, accurate, cost-effective, and efficient than an industry standard cAMP assay.

Benefits of next generation allosteric small molecule drugs





Because allosteric next generation small molecule drugs change the conformation of the receptor, there is no need to use high drug concentrations to achieve the desired effect → this means safer and more effective medicines for patients

Team

Management, Cofounders, & Board

Dr. David Pejoski (co-CEO, COO), Dr. Hesham Hamed (co-CEO, CSO), Prof. Leonardo Scapozza (lead advisor: drug discovery, medchem)

Advisors

Dr. James Rush (Biotech / Pharma executive), Prof. Olivier Michielin (Immuno-Oncology KOL), Prof. Markus Joerger (A2AR clinical expert)

Financing

Secured

>2Mi CHF in non-dilutive grants between 2020 – 2024

Seeking Investments

- 12.1Mi CHF by Q4 2024 to perform 3 years of multi-asset R&D, with exit of Asset 1 & 2, see Roadmap
- Pre-seed round & bridge convertible loans are currently in progress for smaller tickets, closing in Q2 2024

Exit & business model

- Corporate transaction for each asset around first year of clinical trial completion, see Roadmap. Estimated 5 – 15X ROI per asset
- Established pharma interest with multi-billion market for main therapeutic indications
- Pipeline: new drug discovery programs to launch every 18-24 months

Drug Pipeline & Roadmap